Biotech

SPDR(R) S&P(R) Biotech ETF

$78.04

Compare similar ETFs

Fund Size
Dividend
Fees
Current
(R) S&P(R) Biotech ETF XBI
Fund Size
$6.82 Billion
Dividend
0.2%
Fees
0.35%
Biotechnology ETF IBB
Fund Size
$6.93 Billion
Dividend
0.3%
Fees
0.44%
ARK Genomic Revolution ETF ARKG
Fund Size
$1.19 Billion
Dividend
-
Fees
0.75%
NYSE Arca Biotechnology Index Fund FBT
Fund Size
$1.11 Billion
Dividend
0.7%
Fees
-
Biotechnology & Genome ETF PBE
Fund Size
$288 Million
Dividend
0.1%
Fees
-
View 7 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $25.3 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.33 %
Beta Indicates the relationship between the price performance of a share and the market. 0.9834
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 81.34
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -29.28
Profitable Companies 36
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 313.31
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 15.06
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 13.57
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT -266.79
Enterprise Value to Revenue Enterprise value divided by revenue -328.71
Total Debt to Enterprise Value Total debt divided by enterprise value 0.09
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. NaN
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -4369.81%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. -44.65%
Return on Assets Indicates a company's profitability in relation to its total assets. 23.20%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -57.69%

Industries

Healthcare 86.9%
Other 4.1%
N/A 9.0%

Market cap

Micro Cap 1%
Small Cap 20%
Mid Cap 43%
Large Cap 33%
Mega Cap 3%

145 Investments

P/E-Ratio
Total Investment
Weight
State Street Global Advisors logo

State Street Global Advisors

P/E-Ratio
n/a
Total Investment
$448 Million
Weight
7.0%
Neurocrine Biosciences Inc logo

NBIX - Manufacturing

Neurocrine Biosciences Inc

P/E-Ratio
32.1
Total Investment
$163 Million
Weight
2.6%
AbbVie Inc logo

ABBV - Manufacturing

AbbVie Inc

P/E-Ratio
83.8
Total Investment
$156 Million
Weight
2.4%
Gilead Sciences Inc logo

GILD - Manufacturing

Gilead Sciences Inc

P/E-Ratio
21.7
Total Investment
$153 Million
Weight
2.4%
BioMarin Pharmaceutical Inc logo

BMRN - Manufacturing

BioMarin Pharmaceutical Inc

P/E-Ratio
22.6
Total Investment
$152 Million
Weight
2.4%
United Therapeutics Corp logo

UTHR - Manufacturing

United Therapeutics Corp

P/E-Ratio
10.9
Total Investment
$149 Million
Weight
2.3%
Biogen Inc logo

BIIB - Manufacturing

Biogen Inc

P/E-Ratio
12.2
Total Investment
$149 Million
Weight
2.3%
Moderna Inc logo

MRNA - Manufacturing

Moderna Inc

P/E-Ratio
-3.2
Total Investment
$148 Million
Weight
2.3%
Sarepta Therapeutics Inc logo

SRPT - Manufacturing

Sarepta Therapeutics Inc

P/E-Ratio
26.0
Total Investment
$148 Million
Weight
2.3%
Amgen Inc logo

AMGN - Manufacturing

Amgen Inc

P/E-Ratio
25.5
Total Investment
$146 Million
Weight
2.3%
Incyte Corp logo

INCY - Professional, Scientific, and Technical Services

Incyte Corp

P/E-Ratio
569.5
Total Investment
$146 Million
Weight
2.3%
Natera Inc logo

NTRA - Health Care and Social Assistance

Natera Inc

P/E-Ratio
-108.1
Total Investment
$145 Million
Weight
2.3%
Insmed Inc logo

INSM - Manufacturing

Insmed Inc

P/E-Ratio
-14.2
Total Investment
$142 Million
Weight
2.2%
Alnylam Pharmaceuticals Inc logo

ALNY - Manufacturing

Alnylam Pharmaceuticals Inc

P/E-Ratio
-124.7
Total Investment
$142 Million
Weight
2.2%
Regeneron Pharmaceuticals Inc logo

REGN - Manufacturing

Regeneron Pharmaceuticals Inc

P/E-Ratio
14.4
Total Investment
$141 Million
Weight
2.2%
Vaxcyte Inc logo

PCVX - Manufacturing

Vaxcyte Inc

P/E-Ratio
-9.4
Total Investment
$137 Million
Weight
2.2%
Exact Sciences Corp logo

EXAS - Professional, Scientific, and Technical Services

Exact Sciences Corp

P/E-Ratio
-9.4
Total Investment
$136 Million
Weight
2.1%
Vertex Pharmaceuticals Inc logo

VRTX - Manufacturing

Vertex Pharmaceuticals Inc

P/E-Ratio
-240.9
Total Investment
$131 Million
Weight
2.1%
Viking Therapeutics Inc logo

VKTX - Manufacturing

Viking Therapeutics Inc

P/E-Ratio
-25.7
Total Investment
$124 Million
Weight
2.0%
Halozyme Therapeutics Inc logo

HALO - Manufacturing

Halozyme Therapeutics Inc

P/E-Ratio
17.4
Total Investment
$118 Million
Weight
1.9%
Madrigal Pharmaceuticals Inc logo

MDGL - Manufacturing

Madrigal Pharmaceuticals Inc

P/E-Ratio
-17.8
Total Investment
$116 Million
Weight
1.8%
TG Therapeutics Inc logo

TGTX - Manufacturing

TG Therapeutics Inc

P/E-Ratio
289.4
Total Investment
$114 Million
Weight
1.8%
ADMA Biologics Inc logo

ADMA Biologics Inc

P/E-Ratio
n/a
Total Investment
$100 Million
Weight
1.6%
Roivant Sciences Ltd logo

ROIV

Roivant Sciences Ltd

P/E-Ratio
1.8
Total Investment
$96 Million
Weight
1.5%
Ionis Pharmaceuticals Inc logo

IONS - Manufacturing

Ionis Pharmaceuticals Inc

P/E-Ratio
-11.4
Total Investment
$94.5 Million
Weight
1.5%